Welcome to AdisInsight

Please enter your official email address

Email Address
Please enter your official email address

Your email address will be used to create a unique number used exclusively to identify you on AdisInsight. Your email address will not be stored or maintained within AdisInsight. Your unique identifier number will be stored in your browser data on your device. This will allow us to know it’s you when you access AdisInsight from your computer, tablet, or phone. To do this you will need to enter your email address the first time to visit AdisInsight from a new device. After that we will recognize you and you will not have to enter your email again unless you have deleted your browser data. We will use your unique identifier number to provide anonymous information to your subscribing organization to allow them to accurately assess the value AdisInsight delivers. For additional information on how we protect your personal information, please refer to our
privacy policy
.

A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) &gt;6 Months

A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months